M
10b5-1 Plan
$ Value
—
Shares
20,000
Price
—
Filed
Jan 20
Insider
Name
Novack David F
Title
President & COO
CIK
0001573072
Roles
Officer
Transaction Details
Transaction Date
2026-01-15
Code
M
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
146,528
Footnotes
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 6, 2024. | This transaction was executed in multiple trades at prices ranging from $15.585 to $15.665; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax. | Fully vested. | Not applicable.
Filing Info
Novack David F's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-10 | DVAX | U | — |
| 2026-02-10 | DVAX | A | — |
| 2026-02-10 | DVAX | D | — |
| 2026-02-10 | DVAX | A | — |
| 2026-02-10 | DVAX | D | — |
| 2026-02-10 | DVAX | D | — |
| 2026-02-10 | DVAX | D | — |
| 2026-02-10 | DVAX | D | — |
| 2026-02-10 | DVAX | D | — |
| 2026-02-10 | DVAX | D | — |
Other Insiders at DVAX (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| KISNER DANIEL L | — | — | 2026-02-10 |
| SILVERNAIL LAUREN P | — | — | 2026-02-10 |
| CANO FRANCIS | — | — | 2026-02-10 |
| Myers Scott Dunseth | — | — | 2026-02-10 |
|
Slebir John L
SVP General Counsel
|
— | — | 2026-02-10 |
|
Novack David F
President & COO
|
— | — | 2026-02-10 |
|
Spencer Ryan
CEO and Director
|
— | — | 2026-02-10 |
|
MacDonald Kelly
SVP and CFO
|
— | — | 2026-02-10 |
| Sun Elaine D | — | — | 2026-02-10 |
| MacGregor Brent | — | — | 2026-02-10 |
| Deep Track Biotechnology Master Fund, Ltd. | — | — | 2026-02-10 |
| Emini Emilio | — | — | 2026-02-10 |
|
Metzinger Joseph Anthony
VP, Chief Accounting Officer
|
— | — | 2026-02-10 |